A Phase I Study of the CEACAM5 X CD3 Antibody NILK-2301 in Colorectal Cancer

2023-508058-24-01 Protocol LCB-2301-001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 5 Apr 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 2 sites · Protocol LCB-2301-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 12
Countries 1
Sites 2

LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCER

Key facts

Sponsor
NovImmune S.A.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
5 Apr 2024 → ongoing
Decision date (initial)
2024-03-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

LOCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCER

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

NovImmune S.A.

Sponsor organisation
NovImmune S.A.
Address
Chemin Du Pre-Fleuri 15
City
Plan-Les-Ouates
Postcode
1228
Country
Switzerland

Scientific contact point

Organisation
NovImmune S.A.
Contact name
Jose Saro

Public contact point

Organisation
NovImmune S.A.
Contact name
Jose Saro

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 12 2
Rest of world 0

Investigational sites

Spain

2 sites · Ongoing, recruiting
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida Reyes Catolicos 2, Spain, Madrid
Vall D'hebron Institut De Recerca
Oncology, Passeig De La Vall D'hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-04-05 2024-04-12

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-02-01 Spain Acceptable
2024-02-23
2024-03-06
2 NON SUBSTANTIAL MODIFICATION NSM-2 2024-04-29 Spain Acceptable
2024-02-23
2024-04-29
3 SUBSTANTIAL MODIFICATION SM-1 2024-05-23 Spain Acceptable
2024-07-20
2024-07-20
4 SUBSTANTIAL MODIFICATION SM-2 2024-10-14 Spain Acceptable
2024-10-28
2024-10-28
5 SUBSTANTIAL MODIFICATION SM-3 2024-12-27 Spain Acceptable
2025-03-13
2025-03-13
6 NON SUBSTANTIAL MODIFICATION NSM-3 2025-04-11 Spain Acceptable
2025-03-13
2025-04-11
7 SUBSTANTIAL MODIFICATION SM-4 2025-06-23 Spain Acceptable
2025-09-12
2025-10-06